BUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex’s total product sales in the third quarter of 2022.
Avalon GloboCare Announces Closing Of Strategic Investment In Laboratory Services MSO, A Leading Clinical Diagnostics And Reference Laboratory Company; Total Consideration For The Transaction Was $21M
Transaction Expected to Be Accretive to Earnings Through Profit Sharing Agreement
Adds Strong Clinical Synergies to Existing Avalon Portfolio
Marks Launch of New Roll-Up Strategy Targeting Toxicology and
